Evaluating the Role of Neuroinflammation in Low Back Pain (IGNITE)
Primary Purpose
Low Back Pain, Back Pain With Radiation, Back Pain Without Radiation
Status
Unknown status
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Minocycline Hydrochloride 100mg Capsule
Magnetic Resonance-Positron Emission Tomography Imaging
Placebo Capsule
Sponsored by
About this trial
This is an interventional basic science trial for Low Back Pain focused on measuring Microglia, Minocycline, Magnetic Resonance Imaging, Positron Emission Tomography, Pain, Astrocytes, Glia, Human, Back Pain
Eligibility Criteria
Inclusion Criteria:
- the ability to give written informed consent
- fluency in English
- on a stable pain treatment
- Chronic or sub-acute low back pain
Exclusion Criteria:
- no interventional pain procedures during drug trial
- contraindications to MRI and PET scanning (including presence of a cardiac pacemaker or pacemaker wires, metallic particles in the body, vascular clips in the head or previous neurosurgery, prosthetic heart valves, claustrophobia)
- pregnancy or breast feeding
- any use of recreational drugs in the past 6 months
- allergy to minocycline or other tetracyclines, or taking medications known to interact with minocycline
- any other contraindications to minocycline administration
Sites / Locations
- Massachusetts General HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Placebo Comparator
Arm Label
Minocycline Arm
Placebo Arm
Arm Description
Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after a 2-week trial of Minocycline Hydrochloride, 100mg capsule
Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after 2 weeks of treatment with a placebo capsule.
Outcomes
Primary Outcome Measures
Changes in brain PET signal
The investigators will test for the presence of a significant treatment*time interaction in the brain [11C]PBR28 signal.
Secondary Outcome Measures
Changes in spinal PET signal
The investigators will test for the presence of a significant treatment*time interaction in the spinal [11C]PBR28 signal.
Changes in pain outcomes as measured by self report on a 0-100 numerical pain rating scale
The investigators will test for the presence of a significant treatment*time interaction in pain outcomes on a self reported numerical (0-100) pain rating scale.
Full Information
NCT ID
NCT03106740
First Posted
March 28, 2017
Last Updated
September 3, 2021
Sponsor
Marco Loggia
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
1. Study Identification
Unique Protocol Identification Number
NCT03106740
Brief Title
Evaluating the Role of Neuroinflammation in Low Back Pain
Acronym
IGNITE
Official Title
Imaging Glia-mediated NeuroInflammation and Treatment Efficacy (the IGNITE Study)
Study Type
Interventional
2. Study Status
Record Verification Date
September 2021
Overall Recruitment Status
Unknown status
Study Start Date
October 10, 2017 (Actual)
Primary Completion Date
September 2022 (Anticipated)
Study Completion Date
September 2022 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
Marco Loggia
Collaborators
National Institute of Neurological Disorders and Stroke (NINDS)
4. Oversight
Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No
5. Study Description
Brief Summary
In this research, the study team will use brain imaging to evaluate the presence of neuroinflammation in the brains and spinal cords of patients with low back pain. The efficacy of minocycline use for low back pain treatment will also be evaluated by observing whether short-term minocycline administration will reduce neuroinflammation and low back pain symptoms.
Detailed Description
The goal of this research study is to evaluate whether the central nervous systems of those with low back pain are different from those of healthy, pain-free individuals. Specifically, the researchers will test whether "glial cells" (the immune cells of the brain and spinal cord) are more active in patients with low back pain than in healthy volunteers. The investigators' previous study showed that patients with chronic low back pain demonstrated elevations in brain levels of the 18kDa translocator protein (TSPO), a marker of glial activation.
To test this hypothesis, the study team will image the brains and spinal cords of patients suffering from low back pain using integrated magnetic resonance- positron emission tomography (MR-PET), and a radiotracer called [11C]PBR28, which tracks levels of glial activation.
The efficacy of minocycline as a treatment for chronic low back pain will also be evaluated. A recent study demonstrated a statistically significant reduction in pain in those with lumbar radiculopathy after treatment with minocycline, leading the investigators of this study to believe that minocycline may have potential efficacy in treating other back pain populations.
The study team will observe whether a short course of minocycline hydrochloride may reduce glial activation along with self-reported low back pain symptoms. To this end, patients will be evaluated clinically and/or re-scanned after completing a 2-week trial of minocycline or placebo (a sugar pill).
This study will be enrolling individuals who have been suffering from sub-acute (short-term) and chronic low back pain.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Low Back Pain, Back Pain With Radiation, Back Pain Without Radiation, Back Pain Lower Back Chronic, Back Ache, Pain, Chronic
Keywords
Microglia, Minocycline, Magnetic Resonance Imaging, Positron Emission Tomography, Pain, Astrocytes, Glia, Human, Back Pain
7. Study Design
Primary Purpose
Basic Science
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
145 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Minocycline Arm
Arm Type
Experimental
Arm Description
Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after a 2-week trial of Minocycline Hydrochloride, 100mg capsule
Arm Title
Placebo Arm
Arm Type
Placebo Comparator
Arm Description
Evaluation with Magnetic Resonance-Positron Emission Tomography Imaging and/or behavioral pain assessment before and after 2 weeks of treatment with a placebo capsule.
Intervention Type
Drug
Intervention Name(s)
Minocycline Hydrochloride 100mg Capsule
Other Intervention Name(s)
Minocin, Solodyn, Dynacin, Myrac
Intervention Description
Minocycline 100mg will be administered by mouth daily for 2 weeks
Intervention Type
Diagnostic Test
Intervention Name(s)
Magnetic Resonance-Positron Emission Tomography Imaging
Intervention Description
Up to 15 millicuries of [11C]PBR28 will be administered to each subject at each imaging visit, for a maximum of 2 imaging visits.
Intervention Type
Other
Intervention Name(s)
Placebo Capsule
Intervention Description
1 Placebo Capsule (compounded with lactose powder) will be administered by mouth daily for 2 weeks
Primary Outcome Measure Information:
Title
Changes in brain PET signal
Description
The investigators will test for the presence of a significant treatment*time interaction in the brain [11C]PBR28 signal.
Time Frame
2 weeks
Secondary Outcome Measure Information:
Title
Changes in spinal PET signal
Description
The investigators will test for the presence of a significant treatment*time interaction in the spinal [11C]PBR28 signal.
Time Frame
2 weeks
Title
Changes in pain outcomes as measured by self report on a 0-100 numerical pain rating scale
Description
The investigators will test for the presence of a significant treatment*time interaction in pain outcomes on a self reported numerical (0-100) pain rating scale.
Time Frame
2 weeks
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
the ability to give written informed consent
fluency in English
on a stable pain treatment
Chronic or sub-acute low back pain
Exclusion Criteria:
no interventional pain procedures during drug trial
contraindications to MRI and PET scanning (including presence of a cardiac pacemaker or pacemaker wires, metallic particles in the body, vascular clips in the head or previous neurosurgery, prosthetic heart valves, claustrophobia)
pregnancy or breast feeding
any use of recreational drugs in the past 6 months
allergy to minocycline or other tetracyclines, or taking medications known to interact with minocycline
any other contraindications to minocycline administration
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Marco L Loggia, PhD
Phone
617-643-7267
Email
marco@nmr.mgh.harvard.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Erin J Morrissey
Phone
617-726-3695
Email
ejmorrissey@mgh.harvard.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Marco L Loggia, PhD
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hospital
City
Charlestown
State/Province
Massachusetts
ZIP/Postal Code
02129
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Marco Loggia, PhD
Phone
617-643-7267
Email
marco.loggia@mgh.harvard.edu
12. IPD Sharing Statement
Plan to Share IPD
No
Citations:
PubMed Identifier
25582579
Citation
Loggia ML, Chonde DB, Akeju O, Arabasz G, Catana C, Edwards RR, Hill E, Hsu S, Izquierdo-Garcia D, Ji RR, Riley M, Wasan AD, Zurcher NR, Albrecht DS, Vangel MG, Rosen BR, Napadow V, Hooker JM. Evidence for brain glial activation in chronic pain patients. Brain. 2015 Mar;138(Pt 3):604-15. doi: 10.1093/brain/awu377. Epub 2015 Jan 12.
Results Reference
background
PubMed Identifier
25373391
Citation
Vanelderen P, Van Zundert J, Kozicz T, Puylaert M, De Vooght P, Mestrum R, Heylen R, Roubos E, Vissers K. Effect of minocycline on lumbar radicular neuropathic pain: a randomized, placebo-controlled, double-blind clinical trial with amitriptyline as a comparator. Anesthesiology. 2015 Feb;122(2):399-406. doi: 10.1097/ALN.0000000000000508.
Results Reference
background
Learn more about this trial
Evaluating the Role of Neuroinflammation in Low Back Pain
We'll reach out to this number within 24 hrs